Belzarena 1998.

Methods	Randomised clinical trial.
Participants	Country: Portugal. Number randomised: 90. Post‐randomisation drop‐outs: not stated. Revised sample size: 90. Mean age: 42 years. Females: 65 (72.2%). Inclusion criteria: ASA I or II. Exclusion criteria: History of allergy or intolerance to NSAIDs. Concomitant disease that would allow any patient classification criteria ASA III or IV. Previous use of NSAIDs for any indication or self medication in the last 4 weeks. Liver or kidney disease. Pre‐existing asthma. Coagulation disorders or use of anticoagulants.
Interventions	Participants were randomly assigned to 1 of 3 groups. Group 1: tenoxicam 20 mg in 4‐mL saline IV (n = 30). Group 2: tenoxicam 40 mg in 4‐mL saline IV (n = 30). Group 3: saline IV (n = 30).
Outcomes	No outcomes of interest for this review were reported.
Notes	Attempts were made to contact authors in August 2013.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Computer‐generated table".
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "Venipuncture was performed by a nurse who was unaware of the nature of the study". Comment: Further details were not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: This information was not available.
Selective reporting (reporting bias)	High risk	Comment: Mortality and morbidity were not reported.
For‐profit bias	Unclear risk	Comment: This information was not available.